Skip to content
Screener

3M MMM Research, development and related expenses

Research, development and related expenses at other companies

Rein Therapeutics Inc. logo
Rein Therapeutics Inc.RNTX
$500K-19.6%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$32.87M+12.4%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$30.08M-12.6%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$12.93M-6.6%
MapLight Therapeutics, Inc. logo
MapLight Therapeutics, Inc.MPLT
$15.99M+127%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$9.06M+33.9%

Segments

By segment

See full
Safety and Industrial$131M+3.1%
Transportation and Electronics$128M+16.4%
Consumer$33M+6.5%

Other financials

Income statement

See full
Revenue$6.5B+2.5%
Gross profit$2.7B-0.6%
Operating income$984.0M-13.7%
Net income$933.0M+29.0%
EPS (diluted)$1.78+32.8%

Balance sheet

See full
Cash & equivalents$3.0B-20.4%
Total debt$13.2B+0.8%
Total equity$3.0B-31.2%
Total assets$34.9B-8.1%

Cash flow

See full
Operating cash flow$986.0M+203%
CapEx$223.0M+7.2%
Free cash flow$763.0M+166%

Valuation

See full
Market cap$93.9B+16.9%
Enterprise value$104.11B+16.1%
P/E31.3×+10.9×
P/S3.7×+0.5×

Profitability

See full
Gross margin39.4%-1.6pp
Operating margin18.4%-1.1pp
Net margin11.9%-4.1pp
FCF margin15.8%+11.8pp

Returns & leverage

See full
Return on equity82.8%-13.2pp
Debt / equity4.5×+1.4×
Current ratio1.2×-0.5×

Where this comes from

Reported directly by 3M in its filing.

Tagged under the XBRL concept mmm:ResearchDevelopmentAndRelatedExpenses.

The source filing: 3M’s 10-Q, filed July 21, 2026.

Filed
Jul 21, 2026, 12:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000066740-26-000246
(Millions, except per share amounts)Three months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Operating expenses
Cost of sales3,8173,6467,3917,124
Selling, general and administrative expenses1,0611,2671,8052,212
Research, development and related expenses302288610573
Loss on business divestitures33633433
Total operating expenses5,5165,20410,1499,912
Operating income9841,1402,3812,386
Other expense (income), net(136)21738378

Item 1. Financial Statements

FAQ

What is 3M's research, development and related expenses?
3M (MMM) reported research, development and related expenses of $302M in Q2 2026.
How has 3M's research, development and related expenses changed year-over-year?
3M's research, development and related expenses increased by 4.9% year-over-year, from $288M to $302M.
What is the long-term trend for 3M's research, development and related expenses?
Over 3 years (2021 to 2025), 3M's research, development and related expenses has grown at a -16.3% compound annual growth rate (CAGR), from $1.99B to $1.17B.
What does research, development and related expenses mean?
Research and development (R&D) expenses represent the investment made by the company to innovate, develop new products, or improve existing technologies. For technology-driven firms, this is a critical indicator of future competitive positioning and long-term growth potential.

Ask your AI about 3M's research, development and related expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude